IN-DATE
DBP-200SOLID145-SD: CSI Diamondback 360 Peripheral Orbital Atherectomy System, Solid Crown
Sign in to add this product to your favorites!
| Price: | $1,497.99 per box of 1 |
|---|---|
| In Stock: | 0 box of 1 |
We currently do not have this item in stock, but we can email you as soon as it is available.
Additional Details
Abbott CSI Diamondback 360® Solid Crown
CSI Diamondback 360 Peripheral Orbital Atherectomy System, Solid Crown
Product Code: DBP-200SOLID145
- Peripheral Orbital Atherectomy System
- Crown Size: 2.00mm
- Shaft Length: 145cm
- Sheath Size Compatibility: 6F
AccessGUDID Info
- FDA Product Code: MCW
- FDA Product Code Name: Catheter, Peripheral, Atherectomy
- GMDN Term Code: 44307
- GMDN Term Name: Mechanical atherectomy system catheter, peripheral
- GMDN Term Description: A sterile, flexible tube (catheter) intended to be percutaneously introduced for the intraluminal mechanical disruption of atheroma plaque from the walls of peripheral arteries. It has a power-driven cutting or abrasive head for slicing/grinding the atheroma into fragments small enough to be aspirated or absorbed. This device is not intended for use in the coronary, carotid, iliac or renal vasculature. This is a single-use device.
Manufacturer
Cardiovascular Systems, Inc. (CSI), now a part of Abbott, specialized in innovative solutions for the treatment of peripheral and coronary artery disease through its proprietary orbital atherectomy systems. CSI’s flagship technologies include the Diamondback 360® Peripheral Orbital Atherectomy System and the Diamondback 360® Coronary Orbital Atherectomy System, both designed to modify calcified plaque and improve vessel compliance prior to stent placement or balloon angioplasty.
These systems use a diamond-coated crown that orbits within the vessel, sanding away plaque while preserving healthy tissue and facilitating better device delivery. CSI’s focus on challenging arterial disease—particularly in heavily calcified lesions—made it a valuable addition to Abbott’s vascular portfolio following its acquisition in 2023, further expanding minimally invasive treatment options for complex cardiovascular cases.
